IsoRay price target raised to $3.50 from $1.50 at Maxim Maxim raised its price target for IsoRay shares to $3.50 and keeps a Buy rating on the stock. The firm believes IsoRay's recent financing lowers execution risk and points out the company will participate in the Annual Meeting of the American Brachytherapy Society with five papers related to clinical results using cesium-131 products.
IsoRay selected by Chicago prostate cancer center for use in study IsoRay announced that Dr. Brian J. Moran, Director of Chicago Prostate Cancer Center in Westmont, Illinois, has initiated a study of focal prostate cancer treatment using Cesium-131 brachytherapy. Focal therapy is treatment directed solely at the malignancy and its immediate surrounding tissue, rather than the entire gland or organ that is involved. The goal of focal therapy for prostate cancer is to eliminate the targeted cancer while sparing men the side effects that often come with whole gland treatment.